David Unett, Ph.D.
Vice President, Receptor Pharmacology
David Unett has more than 20 years of pharmacology and drug discovery experience in industrial and academic settings. Most recently, he served as VP of Receptor Pharmacology at Arena Pharmaceuticals, leading a team responsible for assay development, high throughput screening, in vitro SAR support and detailed pharmacological characterization of lead candidates. His research team executed over 100 HTS campaigns and provided in vitro pharmacology and cell biology support for numerous projects, including those that identified more than a dozen clinical candidates. David has extensive experience in pharmacology, cell biology, biased signaling, the kinetics of ligand-receptor interactions and persistent signaling. Prior to Arena, he worked with Dr. Michael Lerner on development and commercialization of the melanophore bioassay for GPCRs and other target classes. He was a post-doctoral fellow at the University of Texas at Dallas and UT Southwestern Medical Center and has a Ph.D. in Chemistry from the University of Manchester, UK.